Developing Story
GLP-1 Drugs and Pediatric Nutritional Deficiencies
A new study found nearly 1 in 6 children on GLP-1 drugs (Victoza, Saxenda, Trulicity, Ozempic) developed a diagnosed nutritional deficiency within a year, raising safety concerns about pediatric use of these widely prescribed medications.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
## Overview
A new study has found that children taking GLP-1 medications (such as Victoza, Saxenda, Trulicity, and Ozempic) for weight loss, prediabetes, or type 2 diabetes may face an overlooked risk of nutritional deficiencies (ScienceDaily, September 24).
## Details
Nearly 1 in 6 young patients developed a diagnosed nutritional deficiency within a year of starting treatment, with vitamin D deficiency affecting about 12% of patients (ScienceDaily, September 24).
## Strategic Significance
As GLP-1 drugs see explosive growth in pediatric and adult use, this finding adds to a growing body of safety research with implications for drug liability, FDA labeling requirements, and pharmaceutical litigation. This is a topic likely to recur as more long-term safety data emerges.